Drugs / ME3183
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05268016 | Mar 2022 → May 2023 | psoriasis | Meiji Pharma USA Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ME3183 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05268016 ↗ |
| Route | Oral | “ME3183 administered orally” NCT05268016 ↗ |